Otolaryngology · Wilmington, DE
NPI
1992739676
Since 2006
Specialty
Otolaryngology
Code 207Y00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
1401 Foulk Road, Suite 205
Wilmington, DE, 19803
Phone (302) 998-0300
Groups this clinician bills Medicare through
Medicare paid, 2024
$178K
5,046 services
Medicare patients, 2024
1,019
Average age 75
Drug cost, 2024
$70K
1,935 prescriptions
Company payments, 2025
$780
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Joan F Coker was code 95004 (test - miscellaneous), 1,260 times for 33 patients. In total Joan F Coker billed 5,046 services in 43 codes, and Medicare paid $178K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-08-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95004 Test - Miscellaneous | Office | 1,260 | 33 | $2.77 | $3,489 |
| 95024 Test - Miscellaneous | Office | 1,016 | 33 | $6.25 | $6,351 |
| 69210 Other Organ Systems | Office | 638 | 474 | $34.11 | $22K |
| 99214 Office E&M - Established | Office | 615 | 507 | $95.48 | $59K |
| 99213 Office E&M - Established | Office | 602 | 471 | $59.36 | $36K |
| 95117 Treatment - Miscellaneous | Office | 224 | 134 | $8.61 | $1,928 |
| 99204 Office E&M - New | Office | 204 | 204 | $111.08 | $23K |
| 31575 Other Organ Systems | Office | 81 | 79 | $93.40 | $7,565 |
| G0268 Removal of impacted cerumen (one or both ears) by physician on same date of service as audiologic function testing | Office | 39 | 39 | $36.82 | $1,436 |
| 95115 Treatment - Miscellaneous | Office | 35 | 16 | $6.71 | $235 |
| 31231 Nasal/Sinus Endoscopy | Office | 19 | 19 | $142.55 | $2,708 |
| 99203 Office E&M - New | Office | 17 | 17 | $72.33 | $1,230 |
By year: 2022 $200K for 6,380 services; 2023 $174K for 5,646 services; 2024 $178K for 5,046 services.
Medicare prescription drug claims, 2024
In 2024, the drug Joan F Coker prescribed most often to Medicare patients was Levocetirizine Dihydrochloride, with 640 prescriptions and refills. In total Joan F Coker wrote 1,935 Medicare prescriptions that cost $70K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levocetirizine Dihydrochloride Generic | 640 | 1,785 | 286 | $24K |
| Montelukast Sodium Generic | 288 | 803 | 116 | $5,370 |
| Azelastine Hcl Generic | 165 | 290 | 96 | $4,910 |
| Fluticasone Propionate Generic | 113 | 206 | 43 | $1,723 |
| Fluocinolone Acetonide Oil Generic | 100 | 146 | 74 | $4,255 |
| Omeprazole Generic | 82 | 221 | 38 | $1,525 |
| Amitriptyline Hcl Generic | 77 | 164 | 35 | $908 |
| Prednisone Generic | 73 | 75 | 64 | $140 |
| Mometasone Furoate Generic | 47 | 81 | 26 | $5,943 |
| Meclizine Hcl Generic | 43 | 72 | 28 | $756 |
| Azithromycin Generic | 42 | 42 | 42 | $277 |
| Mupirocin Generic | 26 | 26 | Under 11 | $369 |
| Ipratropium Bromide Generic | 24 | 60 | 20 | $602 |
| Fluocinolone Acetonide Generic | 18 | 22 | 14 | $901 |
| Desloratadine Generic | 16 | 48 | Under 11 | $1,047 |
Brand drugs: 23 claims; generic drugs: 1,912 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Joan F Coker $780 ($780 in general payments such as food, travel and fees) from 11 companies. The largest payer was Takeda Pharmaceuticals U.S.A., Inc. with $195.
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 7 | $195 |
| GlaxoSmithKline, LLC. GSK | 7 | $142 |
| Genentech USA, Inc. ROG.SW | 3 | $85.46 |
| CSL Behring CSL.AX | 3 | $72.15 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $65.45 |
| Kedrion Biopharma, Inc. | 3 | $52.52 |
| Optinose US, Inc. | 3 | $50.46 |
| BioCryst US Sales Co., LLC | 1 | $41.01 |
| ARS Pharmaceuticals Operations, Inc. SPRY | 2 | $31.82 |
| Inspire Medical Systems, Inc. INSP | 1 | $23.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.